Follow the Money to Medical Device & Diagnostic Opportunities
Spotlight on VENITI, Inc.

by

Follow the Money to Medical Device & Diagnostic Opportunities highlights a newly funded medical device or diagnostic company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

VENITI is a U.S. private company that develops devices for the management and treatment of venous insufficiency. It raised $25 million in a completion of a Series D venture capital investment as reported in the PharmSource Lead Sheet on September 15, 2016.

Corporate Highlights

  • VENITI was founded in January 2010
  • Corporate Headquarters: St. Louis, MO
  • Facility: Fremont, CA

Sourcing Opportunities

  • VENITI plans to use the proceeds to support clinical trials and regulatory filings for its VICI VENOUS STENT system and to expand product development and commercial operations.

Device: VICI VENOUS STENT ™
Development Phase: Pivotal studies
Medical Specialty: Cardiovascular/Vascular
Purpose: Device – Therapeutic/Interventional
Type: Implant – Stent
Description: A system comprised of an invasive stent implant and disposable delivery system for the treatment of iliofemoral venous obstruction

Approvals/Clearances:
US – PMA planned
EU – CE Mark approval
US – IDE approval
Australia – TGA approval

Classification: US Class III

Previous Financings

  • March 2015: $17 million in a completed venture capital investment
  • June 2013: $9.7 million in a completed venture capital investment
  • March 2011: $13.5 million in a completed venture capital investment

Medical Device & Diagnostics Pipeline1

Product Candidate Indication Medical Specialty Purpose Type Status
Veni RF Plus ablation system Varicose veins Cardiovascular/
Vascular
Device –
Therapeutic/
Interventional
Laser/Ablation/
Electrosurgical
Approved/Cleared
VICI VENOUS STENT system Iliofemoral venous obstruction Cardiovascular/
Vascular
Device –
Therapeutic/
Interventional
Implant – Stent Pivotal Studies
VICI Verto venous stent system Postthrombotic syndrome Cardiovascular/
Vascular
Device –
Therapeutic/
Interventional
Implant – Stent Marketed/Launched
Vidi Vena Cava Filter Stent retrieval Cardiovascular/
Vascular
Device –
Therapeutic/
Interventional
Instrument/Tool Pilot Studies

Regulatory Approvals and Clearances

Product Candidate Region Approval/Clearance Year of Approval or Clearance
VICI Verto venous stent system EU CE Mark 2016
VICI VENOUS STENT system US IDE Approval 2014
Veni RF Plus ablation system EU CE Mark 2013
VICI VENOUS STENT system EU CE Mark 2013
VICI VENOUS STENT system Australia TGA Approval 2013

1Source: PharmSource Lead Sheet

Contact Information

VENITI, Inc. Key Officers
1610 Des Peres Road, Suite 385 Jeff Elkins, President & CEO
St. Louis, MA 63131 USA Catherin Matthes, CFO
Phone: +1-855-994-4343 Stephen Kao, VP, R&D
Fax: +1-636-628-9991 Daniel Racinella, VP, Technology, Clinical Research & Regulatory Affairs
Web: www.veniti.com Rodney Marcy, Chief Commercialization Officer

Related posts:
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on CVRx, Inc.
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on Avita Medical Ltd.
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on Mainstay Medical International plc.

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu